Clinical Trial Update: Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of Ftortiazinon for complicated urinary tract infections caused by Pseudomonas aeruginosa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pseudomonas Aeruginosa Infection
• Urinary Tract Infection

Drugs mentioned

• Ftortiazinon (Ftortiazinon)

Snippet

Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Conditions: Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa | Phase 2 | Status: COMPLETED